We are live on
!
Find out more
FAM
Fred Alger Management Portfolio holdings
AUM
$22.8B
1-Year Est. Return
64.63%
This Fund
S&P 500
This Quarter
Est. Return
+15.81%
1 Year Est. Return
+64.63%
3 Year Est. Return
+243.99%
5 Year Est. Return
+318.3%
10 Year Est. Return
+1,899.64%
AUM
$19.6B
AUM Growth
+$879M
(+4.7%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-6.05%
Top 10 Holdings %
Top 10 Hldgs %
34.09%
Holding
589
New
74
Increased
137
Reduced
233
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$96.2M |
| 2 |
DraftKings
DKNG
|
+$81.7M |
| 3 |
GE HealthCare
GEHC
|
+$81.1M |
| 4 |
GFL Environmental
GFL
|
+$77M |
| 5 |
Vaxcyte
PCVX
|
+$72.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$187M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$143M |
| 3 |
AbbVie
ABBV
|
+$112M |
| 4 |
Walt Disney
DIS
|
+$99.6M |
| 5 |
HSKA
Heska Corp
HSKA
|
+$80.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.16% |
| 2 | Healthcare | 20.31% |
| 3 | Consumer Discretionary | 12.43% |
| 4 | Industrials | 10.17% |
| 5 | Communication Services | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
AT&T
T
$168B
| $1.12M | 0.01% |
70,437
| – | – |
|
377
Personalis
PSNL
$1.26B
| $1.1M | 0.01% |
584,779
+375,627
| +180% | +$849K |
|
378
MasTec
MTZ
$23.7B
| $1.05M | 0.01% |
+8,932
| New | +$875K |
|
|
JBIO
379
Jade Biosciences
JBIO
$1.14B
| $993K | 0.01% |
1,654
-1,319
| -44% | -$844K |
|
380
Pacific Biosciences
PACB
$435M
| $928K | ﹤0.01% |
+69,780
| New | +$848K |
|
|
381
Walt Disney
DIS
$172B
| $883K | ﹤0.01% |
9,891
-1,051,840
| -99% | -$99.6M |
|
382
RxSight
RXST
$251M
| $878K | ﹤0.01% |
+30,491
| New | +$678K |
|
383
Spotify
SPOT
$105B
| $824K | ﹤0.01% |
5,133
-13,565
| -73% | -$1.97M |
|
384
American Express
AXP
$225B
| $820K | ﹤0.01% |
4,706
| – | – |
|
385
Zoetis
ZTS
$33B
| $772K | ﹤0.01% |
4,484
-22,961
| -84% | -$3.97M |
|
386
Accenture
ACN
$106B
| $743K | ﹤0.01% |
2,407
| – | – |
|
|
IMGN
387
DELISTED
Immunogen Inc
IMGN
| $729K | ﹤0.01% |
+38,658
| New | +$456K |
|
388
Autodesk
ADSK
$51.4B
| $651K | ﹤0.01% |
3,184
| – | – |
|
|
AKRO
389
DELISTED
Akero Therapeutics
AKRO
| $644K | ﹤0.01% |
+13,783
| New | +$632K |
|
390
Agilent Technologies
A
$39.6B
| $609K | ﹤0.01% |
5,063
-32,889
| -87% | -$4.19M |
|
391
Protagonist Therapeutics
PTGX
$8.73B
| $600K | ﹤0.01% |
21,719
+10,114
| +87% | +$253K |
|
392
Deere & Co
DE
$166B
| $596K | ﹤0.01% |
1,471
-95
| -6% | -$36.3K |
|
|
DADA
393
DELISTED
Dada Nexus
DADA
| $584K | ﹤0.01% |
+110,000
| New | +$666K |
|
394
Aptiv
APTV
$12.4B
| $580K | ﹤0.01% |
5,682
| – | – |
|
395
New Oriental
EDU
$9.11B
| $573K | ﹤0.01% |
14,500
-4,000
| -22% | -$160K |
|
396
Tetra Tech
TTEK
$8.75B
| $549K | ﹤0.01% |
16,770
-1,930
| -10% | -$56.8K |
|
397
Twist Bioscience
TWST
$5.3B
| $544K | ﹤0.01% |
+26,587
| New | +$398K |
|
398
Rockwell Automation
ROK
$51B
| $528K | ﹤0.01% |
1,603
| – | – |
|
399
Xylem
XYL
$28.5B
| $518K | ﹤0.01% |
4,601
-1,165
| -20% | -$123K |
|
400
Synopsys
SNPS
$72.5B
| $492K | ﹤0.01% |
1,130
-94
| -8% | -$37.9K |
|
Similar funds
CAM
BA
AM
SAM
CHP
Fred Alger Management's Q2 2023 Portfolio in Review
As of Q2 2023, Fred Alger Management held 589 positions worth $19.6B, up 4.7% from $18.7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Fred Alger Management withdrew a net $1.18B in Q2 2023, closing 78 positions and reducing 233 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Fred Alger Management opened a new position in DraftKings worth $94.2M.
- Fred Alger Management's largest Q2 2023 buy was DraftKings: 3,544,411 shares worth $94.2M.
- Fred Alger Management added most to Meta Platforms (Facebook) in Q2 2023, an estimated $96.2M increase.
- Fred Alger Management's biggest Q2 2023 reduction was Intuit, cutting an estimated $187M.
- Fred Alger Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $143M.
- Fred Alger Management's ten largest holdings make up 34% of its $19.6B portfolio in Q2 2023.
- Fred Alger Management opened 74 new positions and closed 78 in Q2 2023.
- Fred Alger Management's portfolio value rose 4.7% quarter-over-quarter to $19.6B.
Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.